-
公开(公告)号：US20150338396A1
公开(公告)日：2015-11-26
申请号：US14419804
申请日：2013-08-09
发明人： Hisashi NARIMATSU , Atsushi KUNO , Yuzuru IKEHARA , Yasuhiro HASHIMOTO , Keiro SHIROTANI , Kiyomitsu NARA , Yoshinobu KARIYA , Hiromi ITO , Kyoka HOSHI
IPC分类号： G01N33/53 , G01N33/536
CPC分类号： G01N33/5308 , G01N33/536 , G01N33/6854 , G01N2333/42 , G01N2333/4724 , G01N2400/00 , G01N2440/38 , G01N2496/00
摘要： It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.
摘要翻译： 旨在开发并提供一种通过少量步骤快速且具体地检测特定聚糖同种型的方法。 本发明提供了一种聚糖同种型检测方法，其包括定量通过将测试样品与糖链非还原性末端残基结合凝集素和特异性结合聚糖同种型蛋白质部分的抗体混合形成的免疫复合物， 将获得的免疫复合物的量与对照样品不与糖链非还原末端残基结合凝集素混合或与对照蛋白混合时获得的对照免疫复合物的量进行比较， 基于这些量之间的差异，测试样品中存在或不存在感兴趣的聚糖同种型。
-
公开(公告)号：US20170219590A1
公开(公告)日：2017-08-03
申请号：US15327154
申请日：2015-07-22
发明人： Atsushi KUNO , Takashi SATO , Atsushi MATSUDA , Hisashi NARIMATSU , Hiroyuki KAJI , Akira TOGAYACHI , Ken SHIRABE , Yoshihiko MAEHARA
IPC分类号： G01N33/574
CPC分类号： G01N33/57438 , G01N1/30 , G01N33/57492 , G01N2333/70596 , G01N2333/71 , G01N2333/96472 , G01N2400/02
摘要： The problem addressed by the present invention is to provide a marker for detecting hepatocellular carcinoma, wherein the hepatocellular carcinoma marker comprises a glycoprotein that first becomes present in the liver with the occurrence of cancer, without depending on changes in the state of the liver. The present invention provides a hepatocellular carcinoma marker comprising an NPA lectin-binding glycoprotein having an NPA lectin-binding glycan epitope that has at least one of the following properties (1) to (5): (1) the glycan epitope does not include core fucose (fucose α1→6 glycan); (2) the glycan epitope comprises a complex-type glycan having three (four or fewer) mannoses; (3) the glycan epitope does not include a high-mannose-type glycan having five or more mannoses; (4) the glycan epitope comprises a complex-type glycan that does not depend on the property of binding to LCA lectin; and (5) the glycan epitope comprises a complex-type glycan that does not depend on the property of binding to ConA lectin. By detecting the hepatocellular carcinoma marker of the present invention in a test sample, it is possible to determine the presence of hepatocellular carcinoma or the level of progression or malignancy of carcinoma.
-
3.发明申请公开(公告)号：US20210283246A1
公开(公告)日：2021-09-16
申请号：US16972367
申请日：2019-06-06
发明人： Hisashi NARIMATSU , Kiyohiko ANGATA , Hiroyuki KAJI , Atsushi KUNO , Takashi SATO , Yasunori CHIBA , Akira TOGAYACHI , Hiroki SHIMIZU , Maki SOGABE , Takanori WAGATSUMA , Masashi MIZOKAMI , Masaaki KORENAGA , Kazuto TAJIRI , Tatsuhiko OZAWA
IPC分类号： A61K39/29 , C07K14/005 , C07K16/08 , G01N33/576 , A61P31/20
摘要： An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
